Business
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Company to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":"\nCompany to host conference call and webcast on Wednesday, November 5, 2025, at 4:30 p.m. Eastern Time\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nAcadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time.\n\n\nThe conference call will be available on Acadia’s website, acadia.com under the investors section and will be archived there until February 5, 2026. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.\n\n\nAbout Acadia Pharmaceuticals\n\n\nAcadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20251015293381/en/\n\nInvestor Contact:\nAcadia Pharmaceuticals Inc.\nAl Kildani\n(858) 261-2872\[email protected]\n\n\nAcadia Pharmaceuticals Inc.\nJessica Tieszen\n(858) 261-2950\[email protected]\n\n\nSource: Acadia Pharmaceuticals Inc.","length":4499,"tagName":"div"}]